See more : ReGen Biologics Inc. (RGBOQ) Income Statement Analysis – Financial Results
Complete financial analysis of Ackermans & Van Haaren NV (AVHNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ackermans & Van Haaren NV, a leading company in the Engineering & Construction industry within the Industrials sector.
You may be interested
- Phatra Leasing Public Company Limited (PL.BK) Income Statement Analysis – Financial Results
- Hertz Global Holdings, Inc. (HTZWW) Income Statement Analysis – Financial Results
- Hyterra Ltd (HYT.AX) Income Statement Analysis – Financial Results
- PlexBio Co., Ltd. (6572.TWO) Income Statement Analysis – Financial Results
- PHSC plc (PHSC.L) Income Statement Analysis – Financial Results
Ackermans & Van Haaren NV (AVHNF)
About Ackermans & Van Haaren NV
Ackermans & Van Haaren NV engages in the marine engineering and contracting, private banking, real estate and senior care, and energy and resources businesses worldwide. The company operates through five segments: Marine Engineering & Contracting, Private Banking, Real Estate & Senior Care, Energy & Resources, and AvH & Growth Capital. It engages in the marine construction activities, including dredging and civil works on water, as well as offshore activities in the areas of renewable energy, oil and gas, soil and sludge remediation, and aggregate and mineral extraction; real estate development activities; and development of port projects and related industrial zones, as well as offshore wind farms. The company also offers asset management services for various private clients; advisory banking services for entrepreneurs and liberal professionals; and car finance and leasing services through car dealers. In addition, it develops residential and mixed projects; invests in retail and office properties; provides accommodation and care for the elderly; and operates retirement homes. Further, the company produces crude palm oil, rubber, banana, and tea products; manufactures cement; and offers advice, automation, and maintenance services for life science, tank terminal, food and beverage, infrastructure, and chemistry markets. Additionally, it engages in the production and sale of compact biogas installations. Ackermans & Van Haaren NV was founded in 1876 and is headquartered in Antwerp, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.22B | 4.40B | 4.31B | 3.91B | 4.28B | 4.47B | 3.96B | 3.66B | 4.02B | 4.16B | 526.03M | 443.36M | 389.20M | 338.70M | 393.96M | 409.96M | 363.97M | 372.03M | 349.74M | 1.83B |
| Cost of Revenue | 3.34B | 2.87B | 2.11B | 2.03B | 2.23B | 2.31B | 2.01B | 1.78B | 2.04B | 2.30B | 209.78M | 203.56M | 109.61M | 86.17M | 127.01M | 97.97M | 103.81M | 160.49M | 135.71M | 153.63M |
| Gross Profit | 1.88B | 1.53B | 2.20B | 1.88B | 2.05B | 2.16B | 1.96B | 1.88B | 1.98B | 1.87B | 316.25M | 239.81M | 279.59M | 252.54M | 266.96M | 311.99M | 260.17M | 211.55M | 214.02M | 1.67B |
| Gross Profit Ratio | 36.07% | 34.81% | 50.96% | 48.05% | 47.90% | 48.25% | 49.35% | 51.44% | 49.19% | 44.81% | 60.12% | 54.09% | 71.84% | 74.56% | 67.76% | 76.10% | 71.48% | 56.86% | 61.20% | 91.60% |
| Research & Development | 0.00 | 108.00K | 30.00K | 663.00K | 771.00K | 573.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 581.72M | 523.20M | 570.82M | 615.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.01M | 61.71M | 59.89M | 59.24M | 60.27M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 944.75M | 820.28M | 581.72M | 523.20M | 570.82M | 658.14M | 587.75M | 552.70M | 630.03M | 723.79M | 126.17M | 0.00 | 0.00 | 0.00 | 66.01M | 61.71M | 59.89M | 59.24M | 60.27M | 0.00 |
| Other Expenses | 510.40M | -8.41M | 548.00K | -1.58M | 4.44M | 716.00K | 2.39M | 1.79M | 1.57M | 6.81M | 109.40M | -60.12M | 42.03M | 3.86M | 633.00K | 80.09M | 116.31M | -460.39M | -117.72M | -89.78M |
| Operating Expenses | 1.46B | 1.24B | 1.86B | 1.73B | 1.72B | 1.82B | 1.63B | 1.54B | 1.64B | 1.55B | 230.38M | 171.92M | 154.03M | 136.34M | 207.95M | 412.18M | 311.78M | 664.00K | 11.65M | 1.45B |
| Cost & Expenses | 4.79B | 4.11B | 3.98B | 3.76B | 3.95B | 4.13B | 3.64B | 3.32B | 3.68B | 3.85B | 440.16M | 375.47M | 263.64M | 222.51M | 334.96M | 510.15M | 415.59M | 161.15M | 147.37M | 1.60B |
| Interest Income | 36.96M | 17.62M | 11.94M | 13.74M | 20.71M | 10.41M | 10.83M | 11.42M | 10.49M | 14.27M | 3.67M | 16.99M | 23.66M | 19.68M | 18.30M | 22.26M | 26.47M | 28.06M | 22.84M | 22.10M |
| Interest Expense | 58.54M | 37.37M | 33.69M | 39.58M | 35.33M | 36.30M | 42.24M | 49.55M | 42.97M | 44.18M | 11.97M | 13.30M | 21.99M | 69.83M | 14.75M | 24.29M | 23.36M | 74.62M | 70.88M | 78.67M |
| Depreciation & Amortization | 385.29M | 359.59M | 350.55M | 350.77M | 342.95M | 297.04M | 269.32M | 262.91M | 275.01M | 260.30M | 13.66M | 9.54M | 9.22M | 8.67M | 8.21M | 7.15M | 7.18M | 8.12M | 15.34M | 54.25M |
| EBITDA | 1.05B | 913.74M | 975.91M | 714.70M | 846.12M | 847.31M | 824.23M | 733.30M | 864.42M | 720.61M | 394.31M | 191.46M | 247.88M | 226.02M | 249.61M | 301.73M | 346.07M | 359.69M | 345.68M | 318.63M |
| EBITDA Ratio | 20.17% | 20.76% | 21.90% | 17.30% | 19.78% | 18.66% | 18.91% | 20.48% | 19.81% | 17.49% | 68.24% | 37.05% | 71.06% | 81.71% | 46.61% | 60.47% | 97.65% | 102.42% | 51.87% | 13.61% |
| Operating Income | 428.13M | 655.87M | 357.13M | 224.06M | 447.60M | 398.72M | 425.99M | 369.34M | 496.57M | 315.81M | 68.92M | 62.15M | 55.59M | 65.38M | 51.79M | 16.00M | 68.15M | 38.37M | 31.03M | 76.16M |
| Operating Income Ratio | 8.20% | 14.90% | 8.28% | 5.73% | 10.47% | 8.92% | 10.74% | 10.09% | 12.36% | 7.58% | 13.10% | 14.02% | 14.28% | 19.30% | 13.15% | 3.90% | 18.72% | 10.31% | 8.87% | 4.17% |
| Total Other Income/Expenses | 181.46M | 233.72M | 234.53M | 100.29M | 134.64M | 115.25M | 86.69M | 51.51M | 49.87M | 101.81M | 249.90M | 98.51M | 168.74M | 139.63M | 101.67M | 148.31M | 247.37M | 303.71M | 289.78M | 109.56M |
| Income Before Tax | 609.59M | 889.59M | 591.66M | 324.36M | 575.63M | 513.97M | 512.68M | 420.85M | 546.44M | 417.61M | 368.68M | 167.85M | 224.33M | 205.01M | 153.47M | 164.31M | 315.52M | 342.08M | 320.81M | 185.72M |
| Income Before Tax Ratio | 11.67% | 20.21% | 13.72% | 8.30% | 13.46% | 11.49% | 12.93% | 11.50% | 13.60% | 10.03% | 70.09% | 37.86% | 57.64% | 60.53% | 38.96% | 40.08% | 86.69% | 91.95% | 91.73% | 10.16% |
| Income Tax Expense | 102.48M | 82.08M | 79.45M | 46.74M | 61.76M | 72.20M | 57.02M | 54.79M | 108.05M | 88.34M | 20.99M | -42.49M | 9.95M | 12.03M | 7.69M | 9.66M | 12.13M | 12.95M | 14.53M | 24.60M |
| Net Income | 399.19M | 708.66M | 406.81M | 229.79M | 394.90M | 289.64M | 302.53M | 224.24M | 284.08M | 213.65M | 293.90M | 167.34M | 177.51M | 160.80M | 145.78M | 154.65M | 241.39M | 307.60M | 278.99M | 134.79M |
| Net Income Ratio | 7.65% | 16.10% | 9.43% | 5.88% | 9.23% | 6.48% | 7.63% | 6.13% | 7.07% | 5.13% | 55.87% | 37.74% | 45.61% | 47.48% | 37.00% | 37.72% | 66.32% | 82.68% | 79.77% | 7.37% |
| EPS | 12.12 | 21.39 | 12.27 | 6.93 | 11.92 | 8.74 | 9.13 | 6.77 | 8.58 | 6.49 | 8.87 | 5.05 | 6.47 | 4.86 | 4.40 | 4.66 | 9.14 | 9.26 | 8.40 | 4.04 |
| EPS Diluted | 12.12 | 21.37 | 12.26 | 6.93 | 11.89 | 8.71 | 9.09 | 6.74 | 8.54 | 6.47 | 8.85 | 5.05 | 6.46 | 4.85 | 4.39 | 4.64 | 9.11 | 9.23 | 8.40 | 4.04 |
| Weighted Avg Shares Out | 32.94M | 33.13M | 33.15M | 33.14M | 33.14M | 33.14M | 33.14M | 33.14M | 33.13M | 33.12M | 33.14M | 33.13M | 33.12M | 33.09M | 33.14M | 33.21M | 33.20M | 33.23M | 33.23M | 33.36M |
| Weighted Avg Shares Out (Dil) | 32.93M | 33.16M | 33.18M | 33.18M | 33.22M | 33.24M | 33.26M | 33.25M | 33.26M | 33.27M | 33.20M | 33.19M | 33.19M | 33.16M | 33.21M | 33.30M | 33.32M | 33.33M | 33.23M | 33.36M |
Ackermans & van Haaren Trading Update Q3 2024 - AvH is on track towards a net profit well above 400 million euros
Dear shareholder, Dear Madam, Dear Sir, please find attached our press release. Best regards Ackermans & van Haaren Attachment AvH Trading Update Q3 2024 - On track towards a net profit well above 400 million euros
Ackermans & van Haaren and the Delen family confirm their long-term partnership with updated shareholder arrangements in respect of Delen Private Bank and Bank J. Van Breda & Co
Dear shareholder, Dear Madam, Dear Sir, please find attached our press release. Best regards Ackermans & van Haaren Attachment Ackermans & van Haaren and the Delen family confirm their long-term partnership with updated shareholder arrangements
Ackermans & van Haaren invests an additional 5 million euros in Biotalys
Dear shareholder, Dear Madam, Dear Sir, please find attached our press release. Best regards Ackermans & van Haaren Attachment Ackermans & van Haaren invests an additional 5 million euros in Biotalys
Ackermans & van Haaren: Outstanding results in core participations result in a strong increase of AvH's net profit for 1H2024 to EUR 200 million (+17%)
Dear shareholder, Dear Madam, Dear Sir, Please find attached our Half-Year Report 2024. Best regards Ackermans & van Haaren Attachment Ackermans & van Haaren - Half Year Report 2024 - Strong increase of net profit to EUR 200 million (+17%)
Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company
Dear shareholder, Dear Madam, Dear Sir, please find attached our press release. Best regards Ackermans & van Haaren Attachment Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics (press release 26 July 2024)
Ackermans & van Haaren: the General Shareholders' Meeting approves all proposed resolutions by a large majority
Dear shareholder, Dear Madam, Dear Sir, Please find attached our press release on the General Shareholder Meeting of May 27, 2024, which approved all proposed resoltuions by a large majority, including the approval of the financial statements, a gross dividend...
Ackermans & van Haaren reports outstanding Q1-results at both DEME and at the private banks Delen and Van Breda, and gives confirmation of guidance: net profit of 2024 expected to be higher than last year
Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren has published today its Trading Update on the 1st quarter of 2024, with the following key items: Outstanding Q1-results at both DEME and at the private banks Delen and Van...
Ackermans & van Haaren realised a net profit of 399.2 million euros, thanks to a record performance of its core participations
Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren realised a net profit of 399.2 million euros, thanks to a record performance of its core participations. Growth of equity per share of 9.6% over 2023 and 9.8% compounded over...
Ackermans & van Haaren: Well on track to post a solid set of results for the full year 2023
Dear shareholder, Dear Madam, Dear Sir, The board of directors confirms that Ackermans & van Haaren is well on track to post a solid set of results for the full year 2023. The contribution from core segments of the group...
Ackermans & van Haaren realised a net profit of 170.7 million euros over the first half of 2023 and is well on track to deliver another strong set of results for the whole year of 2023
Dear shareholder, Dear Madam, Dear Sir, In spite of a more challenging economic environment, the contribution of the core segments of 149.6 million euros is down only 4% from H1 2022. Delen Private Bank and Bank Van Breda have further...
Source: https://incomestatements.info
Category: Stock Reports